<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03476460</url>
  </required_header>
  <id_info>
    <org_study_id>PNIC-Na</org_study_id>
    <nct_id>NCT03476460</nct_id>
  </id_info>
  <brief_title>Sodium Chloride and Contrast Nephropathy</brief_title>
  <official_title>Efficacy of Oral Sodium Chloride vs iv Sodium Chloride in the Prevention of Contrast Nephropathy in Outpatients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II, open, non-inferiority, randomized and controlled clinical trial is aimed to
      ascertain the incidence of contrast nephropathy in outpatients undergoing CT scan with
      contrast.

      Patients will be randomized to receive oral prophylaxis with capsules of sodium chloride and
      free water ingestion or prophylaxis with sodium chloride 0.9% intravenous solution.

      The total dose (mmol) of sodium chloride will be the same regardless administration via. The
      contrast will be iodixanol.

      Patients &gt;65 years, of both sexes, with at least one of the following criteria: diabetes,
      stable heart failure or chronic kidney disease (estimated glomerular filtration rate between
      30 and 60 ml/min), undergoing CT scan with contrast, and who give written informed consent,
      will be included in the study. Patients with estimated glomerular filtration rate &lt;30 ml/min,
      serum potassium &lt;3.5 mEq/L, infusion of iodine contrast in the previous 15 days,
      administration of nephrotoxic drugs in the previous 72 hours or expected in the following
      hours after contrast infusion, decompensated chronic conditions (heart failure, chronic
      obstructive pulmonary disease, hypertension), allergy to iodine contrast, or the presence of
      hyperchloremia or hypernatremia, will be excluded from the study.

      Contrast nephropathy will be defined as the increase of serum creatinine &gt;0.3 mg/dL from
      baseline, or the reduction of estimated glomerular filtration rate (MDRD-4) &gt;25% from
      baseline, in the first 48 hours after contrast administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase II, open, non-inferiority, randomized and controlled clinical trial is aimed to
      ascertain the incidence of contrast nephropathy in outpatients undergoing CT scan with
      contrast.

      Patients will be randomized to receive oral prophylaxis with capsules of sodium chloride and
      free water ingestion or prophylaxis with sodium chloride 0.9% intravenous solution.

      In those patients randomly allocated to oral prophylaxis (n=133), patients will receive
      capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride,
      patients will take 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the
      48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose
      of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8
      hours), at the moment of contrast injection and 12 hours after the injection of contrast. In
      those patients randomly allocated to receive sodium chloride 0.9% intravenous solution
      (n=133), patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous
      contrast injection and 2 ml/kg during the 4 hours after contrast injection. The total dose
      (mmol) of sodium chloride will be the same regardless administration via. The contrast will
      be iodixanol (320 mg of iodine/ml, in 100 ml, at an infusion rate of 2-5 ml/sec).

      Patients &gt;65 years, of both sexes, with at least one of the following criteria: diabetes,
      stable heart failure or chronic kidney disease (estimated glomerular filtration rate between
      30 and 60 ml/min), undergoing CT scan with contrast, and who give written informed consent,
      will be included in the study. Patients with estimated glomerular filtration rate &lt;30 ml/min,
      serum potassium &lt;3.5 mEq/L, infusion of iodine contrast in the previous 15 days,
      administration of nephrotoxic drugs in the previous 72 hours or expected in the following
      hours after contrast infusion, decompensated chronic conditions (heart failure, chronic
      obstructive pulmonary disease, hypertension), allergy to iodine contrast, or the presence of
      hyperchloremia or hypernatremia, will be excluded from the study.

      Contrast nephropathy will be defined as the increase of serum creatinine &gt;0.3 mg/dL from
      baseline, or the reduction of estimated glomerular filtration rate (MDRD-4) &gt;25% from
      baseline, in the first 48 hours after contrast administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of contrast nephropathy during the first 48 hours after contrast administration</measure>
    <time_frame>During the first 48 hours after contrast administration</time_frame>
    <description>The incidence of contrast nephropathy, defined as the increase of serum creatinine &gt;0.3 mg/dL from baseline, or the reduction of estimated glomerular filtration rate (MDRD-4) &gt;25% from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of biomarkers of contrast nephropathy during the first 48 hours after contrast administration</measure>
    <time_frame>During the first 48 hours after contrast administration</time_frame>
    <description>To evaluate the clinical utility of different biomarkers for the early diagnosis of contrast nephropathy (cystatin C, MicroRNAs, NGAL, KIM-1, NAG, t-gelsolina, GM2AP, creatinine)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Kidney Failure, Acute</condition>
  <condition>Heart Failure</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Oral sodium chloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, patients will take 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous sodium chloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral sodium chloride</intervention_name>
    <description>Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, with 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.</description>
    <arm_group_label>Oral sodium chloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous sodium chloride</intervention_name>
    <description>Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.</description>
    <arm_group_label>Intravenous sodium chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;65 years,

          -  Both sexes,

          -  With at least one of the following criteria: diabetes or stable heart failure or
             chronic kidney disease (estimated glomerular filtration rate between 30 and 60
             ml/min),

          -  Undergoing CT scan with contrast

          -  Written informed consent.

        Exclusion Criteria:

          -  Estimated glomerular filtration rate &lt;30 ml/min,

          -  Serum potassium &lt;3.5 mEq/L,

          -  Infusion of iodine contrast in the previous 15 days,

          -  Administration of nephrotoxic drugs in the previous 72 hours or expected in the
             following hours after contrast infusion,

          -  Decompensated chronic conditions (heart failure, chronic obstructive pulmonary
             disease, hypertension),

          -  Allergy to iodine contrast,

          -  Presence of hyperchloremia or hypernatremia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Manzano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis Manzano, MD, PhD</last_name>
    <phone>34913368921</phone>
    <email>luis.manzano@uah.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Manzano, MD, PhD</last_name>
      <phone>34913368921</phone>
      <email>luis.manzano@uah.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Section 4: Contrast-induced AKI. Kidney Int Suppl (2011). 2012 Mar;2(1):69-88.</citation>
    <PMID>25018920</PMID>
  </results_reference>
  <results_reference>
    <citation>Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002 May 14;105(19):2259-64.</citation>
    <PMID>12010907</PMID>
  </results_reference>
  <results_reference>
    <citation>McCullough PA, Stacul F, Becker CR, Adam A, Lameire N, Tumlin JA, Davidson CJ; CIN Consensus Working Panel. Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary. Rev Cardiovasc Med. 2006 Fall;7(4):177-97.</citation>
    <PMID>17224862</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta R, Gurm HS, Bhatt DL, Chew DP, Ellis SG. Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv. 2005 Apr;64(4):442-8.</citation>
    <PMID>15789398</PMID>
  </results_reference>
  <results_reference>
    <citation>Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006 Apr;(100):S11-5. Review.</citation>
    <PMID>16612394</PMID>
  </results_reference>
  <results_reference>
    <citation>Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ; Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003 Feb 6;348(6):491-9.</citation>
    <PMID>12571256</PMID>
  </results_reference>
  <results_reference>
    <citation>Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004 Oct 6;44(7):1393-9.</citation>
    <PMID>15464318</PMID>
  </results_reference>
  <results_reference>
    <citation>Thomsen HS. How to avoid CIN: guidelines from the European Society of Urogenital Radiology. Nephrol Dial Transplant. 2005 Feb;20 Suppl 1:i18-22. Review.</citation>
    <PMID>15705944</PMID>
  </results_reference>
  <results_reference>
    <citation>Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int. 2005 Jul;68(1):14-22. Review.</citation>
    <PMID>15954892</PMID>
  </results_reference>
  <results_reference>
    <citation>Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B, Uder M. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology. 2005 Jun;235(3):843-9. Epub 2005 Apr 21.</citation>
    <PMID>15845795</PMID>
  </results_reference>
  <results_reference>
    <citation>Asif A, Epstein M. Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 2004 Jul;44(1):12-24. Review.</citation>
    <PMID>15211433</PMID>
  </results_reference>
  <results_reference>
    <citation>Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004 May 19;291(19):2328-34.</citation>
    <PMID>15150204</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoshino A, Enomoto S, Kawahito H, Kurata H, Nakahara Y, Nakamura T. [Prevention of contrast-induced nephropathy using cardiac catheterization combined with hydration, oral N-acetylcysteine, sodium bicarbonate and iso-osmolar contrast agents]. J Cardiol. 2007 Aug;50(2):119-26. Japanese.</citation>
    <PMID>17802695</PMID>
  </results_reference>
  <results_reference>
    <citation>Ozcan EE, Guneri S, Akdeniz B, Akyildiz IZ, Senaslan O, Baris N, Aslan O, Badak O. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007 Sep;154(3):539-44.</citation>
    <PMID>17719303</PMID>
  </results_reference>
  <results_reference>
    <citation>Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, Michev I, Montorfano M, Carlino M, Cosgrave J, Ricciardelli B, Colombo A. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007 Mar 13;115(10):1211-7. Epub 2007 Feb 19.</citation>
    <PMID>17309916</PMID>
  </results_reference>
  <results_reference>
    <citation>Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, Hewett J. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. 2003 Jan;93(1):C29-34.</citation>
    <PMID>12411756</PMID>
  </results_reference>
  <results_reference>
    <citation>Dussol B, Morange S, Loundoun A, Auquier P, Berland Y. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant. 2006 Aug;21(8):2120-6. Epub 2006 Apr 12.</citation>
    <PMID>16611682</PMID>
  </results_reference>
  <results_reference>
    <citation>Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin C-based formulas for prediction of glomerular filtration rate in patients with chronic kidney disease. Nephron Clin Pract. 2010;114(2):c118-26. doi: 10.1159/000254384. Epub 2009 Nov 3.</citation>
    <PMID>19887832</PMID>
  </results_reference>
  <results_reference>
    <citation>Keyes R, Bagshaw SM. Early diagnosis of acute kidney injury in critically ill patients. Expert Rev Mol Diagn. 2008 Jul;8(4):455-64. doi: 10.1586/14737159.8.4.455. Review.</citation>
    <PMID>18598227</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferguson MA, Vaidya VS, Bonventre JV. Biomarkers of nephrotoxic acute kidney injury. Toxicology. 2008 Mar 20;245(3):182-93. doi: 10.1016/j.tox.2007.12.024. Epub 2008 Jan 4. Review.</citation>
    <PMID>18294749</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2018</study_first_posted>
  <last_update_submitted>March 25, 2018</last_update_submitted>
  <last_update_submitted_qc>March 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Ramon y Cajal</investigator_affiliation>
    <investigator_full_name>Luis Manzano Espinosa</investigator_full_name>
    <investigator_title>MD, PhD, Chief of Internal Medicine department</investigator_title>
  </responsible_party>
  <keyword>Acute kidney failure</keyword>
  <keyword>CT scan</keyword>
  <keyword>Iodine contrast</keyword>
  <keyword>Sodium chloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

